Revolutionizing treatment of advanced melanoma with immunotherapy.
Autor: Carreau, Nicole; Pavlick, Anna
Publication year: 2022
Surgical oncology
issn:1879-3320 0960-7404
doi: 10.1016/j.suronc.2019.01.002
Abstract:
Until immunotherapy was developed, a diagnosis of metastatic melanoma was most often fatal. Programmed death receptor-1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibodies have been shown to work synergistically to treat metastatic disease throughout the body and brain. Today, over half of patients diagnosed with stage IV disease are alive after 3 years. In the adjuvant setting, 70% patients remain disease free with PD-1 blockade after 1 year. These treatments are generally safe and well tolerated. However, treatment-related endocrinopathies require long-term medications. With better therapies producing more durable responses, advanced cutaneous melanoma is dramatically more manageable now than ever before.
Language: eng
Rights: Copyright © 2019. Published by Elsevier Ltd.
Pmid: 30691991
Tags: Humans; *Antineoplastic Agents/therapeutic use; Immunotherapy; Melanoma; Antibodies, Monoclonal; *Melanoma/therapy; *Skin Neoplasms/therapy; Checkpoint; Programmed Cell Death 1 Receptor/therapeutic use
Link: https://pubmed.ncbi.nlm.nih.gov/30691991/
